Merck & Co. company profile
Company profile
Merck & Co. has 73,000 employees and is headquartered in Rahway, United States.
Customers for Merck & Co., Inc.'s human health medicines, vaccines and animal health products are spread across markets worldwide, with the United States and EMEA accounting for most of its revenue. The company sells prescription medicines and vaccines for human patients, including Keytruda, Gardasil, Januvia and Winrevair, and veterinary pharmaceuticals for livestock and companion animals, under brands such as Bravecto, Nobivac NXT and Bovilis. It also offers Allflex Livestock Intelligence solutions and has collaboration agreements with Daiichi Sankyo, AstraZeneca, Moderna and LaNova.
In the fiscal year ended December 2025, revenue reached $65.0 billion, up 1.3% from the previous year, and net income was $18.3 billion. The United States accounted for 56.2% of revenue, EMEA for 22.4% and Latin America for 5.2%. The company had 73,000 employees and is headquartered in Rahway, New Jersey.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Headquarters
- 126 East Lincoln Avenue, 07065, Rahway
- Employees
- 73,000
- Chief executive
- Robert Davis
- Founded
- 2000
- Fiscal year
- January - December
- Listing
- MRK · NYSE
- Currency
- USD
- ISIN
- US58933Y1055
- Website
- merck.com
Merck & Co. and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Merck & Co.MRK | United States | $364.26B | 73,000 | 35.2% | 147.8 |
| AbbVieABBV | United States | $521.5B | 57,000 | 36.6% | 50.6 |
| AmgenAMGN | United States | $251.89B | 31,500 | 34.1% | 27.0 |
| Gilead SciencesGILD | United States | $208.48B | 17,000 | 38.2% | — |
| Johnson & JohnsonJNJ | United States | $687.89B | 138,200 | 26.6% | 43.4 |
| PfizerPFE | United States | $164.67B | 75,000 | 29.1% | 41.3 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
